DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c4bbb5/oman_pharmaceutica) has announced the addition of the "Oman Pharmaceuticals and Healthcare Report Q3 2011" report to their offering.
This report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Oman's pharmaceuticals and healthcare industry.
Regionally speaking, Oman represents a moderately attractive market. While its positives include well-developed healthcare and an improved intellectual property (IP) environment, Oman is a small market, limited by a modest population of under 3mn. Nevertheless, the traditionally dominant patented drugs segment will continue to attract multinational interest.
Headline Expenditure Projections:
- Pharmaceuticals: OMR133mn (US$345mn) in 2010 to OMR144mn (US$373mn) in 2011; +8.1% in local currency terms and +8.1% in US dollar terms. Forecast unchanged from Q211.
- Healthcare: OMR576mn (US$1.50bn) in 2010 to OMR632mn (US$1.64bn) in 2011; +9.7% in local currency terms and +9.7% in US dollar terms. Forecast down from Q211 due to macroeconomic factors.
- Medical devices: OMR38mn (US$100mn) in 2010 to OMR41mn (US$108mn) in 2011; +8.0% in local currency terms and +8.0% in US dollar terms. Forecast unchanged from Q211.
Business Environment Rating: Oman again ranks in ninth place within the 19 key markets surveyed by our proprietary Business Environment Rating (BER) matrix for the Middle East and Africa (MEA) region. However, its composite score is somewhat lower (-3.1%) than in the previous quarter, on the back of the lower score awarded for Oman's industry rewards variable.
Key Trends & Developments Revealed in this new In-depth Report:
Healthcare services providers in Malaysia are looking to benefit from the potential of medical tourism in Oman. Faith Tang, assistant manager of international marketing at Malaysia-based Sime Darby Healthcare, noticed the scope for offering treatments for blood diseases, paediatric oncology and obesity in Oman. Tang added that Malaysian companies would benefit if they offer treatments not available in Oman and provide speciality services such as bone marrow and liver transplants.
The Ministry of Health (MoH) of Oman is also seeking to eliminate tuberculosis (TB) through anti-TB efforts such as a training workshop organised for healthcare personnel for the disease on March 30 2011, reported Oman Daily Observer. The spread of the disease in the country has decreased by more than 75% to 213 cases in 2010.
Companies Mentioned:
Zynova/Oman Pharmaceutical Products Company (OPPC)
National Pharmaceutical Industries (NPI)
Novartis
GlaxoSmithKline
Sanofi-Aventis
Johnson & Johnson
For more information visit http://www.researchandmarkets.com/research/c4bbb5/oman_pharmaceutica